Message_id,From,Time_stamp,Text
<32060692.1075840772391.JavaMail.evans@thyme>,twg298@yahoo.com,2002-01-08 19:56:03,The Biotech Sector Fpst STOCKS ARE DOWN ACROSS THE BOARD Where can the sophisticated investor go for returns that beat the market THE BIOTECH SECTOR IS STILL HOT Consider this January CBS MarketWatch Analyst Mark Augustine at USB Piper Jaffray believes will be a strong year for the biotechnology sector due to improving industry fundamentals and a favorable market and economic environment He also feels merger speculation could hit developmentstage companies December Washington Post As investors look for new places to park their money biotech firms are grabbing a larger share of a shrinking pool of venture capital What were seeing is a greater interest in the life sciences sector than any other sector Recent progress by genetic researchers worldwide including the wellknown Human Genome Projects effort to map the human genome has grabbed the worlds attention with its vast possibilities and made it a very attractive field for speculative investors Many experts agree that the future of medicine is in genomic research Millions of people die each year from disease and thousands more die from negative responses to drugs The science of genomics promises to improve lives by identifying the genes that cause disease so doctors can attack a disease before symptoms ever become visible and determining which drugs should be prescribed to a person based on their unique genetic makeup The entire pharmaceutical industry has developed drugs against only about genes If common diseases are each caused by different genes there may be disease genes out there so the vast majority of the disease genes will not have existing drugs to combat them Would you be interested in jumpstarting your portfolio with an aggressive Biotech investment Led by a Harvardtrained PhD a new developmentstage company is taking advantage of the recent advances in genomics and information technology to solve as many common diseases as possible within the next five years by identifying as many of the genes as possible which contribute to a specific disease The Companys goal is nothing short of a medical revolution they aim to change the way medicine is practiced Instead of waiting for symptoms to develop they intend to diagnose disease before any signs are visible They already own three potentially blockbuster clinical provisional patents that are ready for immediate licensing It is estimated by Daniel Cohen of Genset that a single disease gene is worth from to million dollars This new company expects to find hundreds of these It is estimated by Daniel Cohen of Genset that a single disease gene is worth from to million dollars This new company expects to find hundreds of these The company just received an infusion of M in venture capital and began trading less than two months ago This is truly a ground floor opportunity The companys stated goal is to be bought out for a minimum of M or get listed on the NASDAQ Small Cap or NASDAQ National Market Systems Exchange Either of these outcomes should be a boon to the Companys shareholders Want to find out more Please enter your email address in the box below and hit the submit to request a free report on this exciting opportunity Disclaimer The contents of this mailing are provided for informational purposes only Information in this mailing has been obtained from publicly available sources deemed to be reliable but the Sender makes no guarantee as to the accuracy or completeness of this data Under no circumstances does the information in this mailing represent a recommendation to buy or sell securities of any kind Information is provided for informational purposes only and Sender shall not be liable for any errors or omissions or for any actions taken in reliance thereon Sender was compensated shares of stock in the above company by a third party to provide corporate exposure services including the distribution of this mailing List RemovalOPTOUT Option Click Here
